Additonal Manufacturing Technology Sample Clauses

Additonal Manufacturing Technology. Drug Substance 01 [*][Exclusion of confidential technical information] 02 [*][Exclusion of confidential technical information] [*] Confidential Treatment Requested 03 [*][Exclusion of confidential technical information] [*] Confidential Treatment Requested EXHIBIT B - LICENSED PATENTS Title: "Targeted cytotoxic anthracycline analogs" Owner: Administrators of the Tulane Educational Fund Licensee: AEZS Internal No.: 950154 PH Internal_No Country Application_No Application_Date Patent_No Granted_Date Expiry_Date CN-PCT 950154 PH China (PRC) 96198605.0 14.11.1996 ZL96198605.0 04.02.2004 14.11.2016 HK 950154 PH Hong Kong 99102273.6 24.05.1999 HK 1017363 29.10.2004 14.11.2016 [*] Confidential Treatment Requested EXHIBIT C - DEVELOPMENT PLAN Activity Duration Start End [*] [Exclusion of competitive sensitive information] [*] Confidential Treatment Requested EXHIBIT D - LICENSED COMPOUNDS Zoptarelin doxorubicin triacetate INN: Zoptarelin doxorubicin (free base) CAS-Number: 139570-93-7 (free base) Company Code: AEZS-108 Additional Codes: AN-152, ZEN-008, D-81858, D-26230 Chemical Name: 5-oxo-L-prolyl-L-histidyl-l-tryptophyl-L-seryl-L-tyrosyl-N6-[5-(2-{(2S,4S)-4-[(3amino-2,3,6- trideoxy-á-L-lyxo-hexopyranosyl)oxyl]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo- 1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-oxoethoxy)-5-oxopentanoyl]-D-lysine-L-leucyl-L- arginyl-L-prolylglycinamide Formula: Code Formula M.W. Salt form AEZS-108 D-81858 C97H129N19O32 2073.17 triacetate salt C91H117N19O26 1 893.01 free base AN-152 D-26230 C93H118N19O28F3 2 007.04 mono TFA salt Chemical Structure: [*] Confidential Treatment Requested EXHIBIT E - LICENSED PRODUCTS Substance code: AEZS-108 Substance name: Zoptarelin doxorubicin [*] [Exclusion of confidential technical information] Report no.: [*][Exclusion of confidential technical information] Title: [*][Exclusion of confidential technical information] technical information]
AutoNDA by SimpleDocs
Additonal Manufacturing Technology. Drug Substance 01 [*] [Exclusion of confidential technical information] # 02 [*] [Exclusion of confidential technical information] # 03 [*] [Exclusion of confidential technical information] # 04 [*] [Exclusion of confidential technical information] # Exhibit B Technical Assistance Plan I, Assistance in providing necessary information and materials AEZS shall provide the information and materials described in Exhibit A and Exhibit C to Sinopharm A-Think.

Related to Additonal Manufacturing Technology

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Manufacturing Intrexon shall have the option and, in the event it so elects, shall use Diligent Efforts, to perform any manufacturing activities in connection with the Aquaculture Program that relate to the Intrexon Materials, including through the use of a suitable Third Party contract manufacturer. To the extent that Intrexon so elects, Intrexon may request that AquaBounty and Intrexon establish and execute a separate manufacturing and supply agreement, which agreement will establish and govern the production, quality assurance, and regulatory activities associated with manufacture of Intrexon Materials. Except as provided in Section 4.1, any manufacturing undertaken by Intrexon pursuant to the preceding sentence shall be performed in exchange for cash payments equal to Intrexon’s Fully Loaded Cost in connection with such manufacturing, on terms to be negotiated by the Parties in good faith. In the event that Intrexon does not manufacture Intrexon Materials or bulk quantities of other components of AquaBounty Products, then Intrexon shall provide to AquaBounty or a contract manufacturer selected by AquaBounty and approved by Intrexon (such approval not to be unreasonably withheld) all Information Controlled by Intrexon that is (a) related to the manufacturing of such Intrexon Materials or bulk qualities of other components of AquaBounty Products for use in the Field and (b) reasonably necessary to enable AquaBounty or such contract manufacturer (as appropriate) for the sole purpose of manufacturing such Intrexon Materials or bulk quantities of other components of AquaBounty Products. The costs and expenses incurred by Intrexon in carrying out such transfer shall be borne by Intrexon. Any manufacturing Information transferred hereunder to AquaBounty or its contract manufacturer shall not be further transferred to any Third Party, including any Product Sublicensee, or any AquaBounty Affiliate without the prior written consent of Intrexon; provided, however, that Intrexon shall not unreasonably withhold such consent if necessary to permit AquaBounty to switch manufacturers.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Manufacturing Rights Manufacturing Rights will be governed by Attachment 6.

  • Joint Manufacturing Committee A joint manufacturing committee (the “Joint Manufacturing Committee” or “JMC”) will be established pursuant to the Supply Agreement. The roles and responsibilities of the JMC shall be as specified in the Supply Agreement.

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

Time is Money Join Law Insider Premium to draft better contracts faster.